| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/01/2010 | WO2010034656A1 Isoxazolo[4,5]pyridin-3-yl-piperazin derivatives useful as modulatorsof dopamine d3 receptors |
| 04/01/2010 | WO2010034649A1 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
| 04/01/2010 | WO2010034648A1 Pyridinylpiperazin derivatives useful as modulators of dopamine d3 receptors |
| 04/01/2010 | WO2010034646A1 Benzo[d]isoxazol-3-yl-piperazin derivatives useful as modulators of dopamine d3 receptors |
| 04/01/2010 | WO2010034642A1 Reducing astringency in compositions containing phenolic compounds |
| 04/01/2010 | WO2010034590A1 Composition for treating disease |
| 04/01/2010 | WO2010034512A1 Compounds with antimalarial activity |
| 04/01/2010 | WO2010034500A1 Substituted imidazopyridine, imidazopyrazine, imidazopyridazine and imidazopyrimidine derivatives as melanocortin-4 receptor antagonists |
| 04/01/2010 | WO2010034497A2 Compacted cinacalcet |
| 04/01/2010 | WO2010034414A1 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma |
| 04/01/2010 | WO2010034384A1 Novel crystal form of calcium-3-acetyl aminopropane-1-sulfonate |
| 04/01/2010 | WO2010034344A1 Ph-dependent controlled release pharmaceutical composition for non-opioids with resistance against the influence of ethanol |
| 04/01/2010 | WO2010034342A1 Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol |
| 04/01/2010 | WO2010034269A1 Use of 2,5-dihydroxy-3,6-dimethylpyrazine and derivatives thereof in medicaments preparation |
| 04/01/2010 | WO2010034243A1 Novel gene cluster |
| 04/01/2010 | WO2010034212A1 Phenoxy acetic acid pyrazine ester derivatives, the preparation methods and uses thereof |
| 04/01/2010 | WO2010034118A1 Nitric oxide releasing amino acid ester compound, composition and method of use |
| 04/01/2010 | WO2010034110A1 Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists |
| 04/01/2010 | WO2010034105A1 Hepatitis c inhibitor compounds |
| 04/01/2010 | WO2010017545A3 Triazole compounds that modulate hsp90 activity |
| 04/01/2010 | WO2010017240A3 Aurora kinase modulators and methods of use |
| 04/01/2010 | WO2010016965A9 Methods for treating injury associated with exposure to an alkylating species |
| 04/01/2010 | WO2010015965A3 Methods and compositions for treating neuronal damage and modulating transient receptor potential channels |
| 04/01/2010 | WO2010015849A3 Pyrazolo [3,4] pyrimidin-4-yl derivatives and their uses to treat diabetes and obesity |
| 04/01/2010 | WO2010015827A3 Phosphate binding materials and their uses |
| 04/01/2010 | WO2010014990A3 Method of promoting neurogenesis by modulating secretase activities |
| 04/01/2010 | WO2010014836A3 Tgr5 modulators and methods of use thereof |
| 04/01/2010 | WO2010013231A3 Coagulation factor modulation for controlling transplant organ size |
| 04/01/2010 | WO2010011626A3 Pyridinyl modulators of ϒ-secretase |
| 04/01/2010 | WO2010010157A3 INHIBITORS OF 11beta-HYDROXYSTEROID DEHYDROGENASE 1 |
| 04/01/2010 | WO2010009369A3 Methods and materials for the treatment of acne |
| 04/01/2010 | WO2010008864A3 Cycloalkane[b]indole angtagonists of prostaglandin d2 receptors |
| 04/01/2010 | WO2010006904A3 Crystalline forms of rabeprazole sodium |
| 04/01/2010 | WO2010006125A3 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs |
| 04/01/2010 | WO2010006026A3 Improving renal function with quercetin-containing compositions |
| 04/01/2010 | WO2010005836A9 Use of rifalazil to treat colonic disorders |
| 04/01/2010 | WO2010005257A3 Controlled-release pharmaceutical preparation containing nicorandil |
| 04/01/2010 | WO2010003057A3 Treating cancer |
| 04/01/2010 | WO2010002845A3 Quinazoline derivatives |
| 04/01/2010 | WO2010002655A3 Pyrimidine derivatives as kinase inhibitors |
| 04/01/2010 | WO2010001102A3 Photochemical internalisation of kinase inhibitors |
| 04/01/2010 | WO2009158007A3 Methods and compositions for therapeutic treatment |
| 04/01/2010 | WO2009156864A3 Substituted alkyl pyrimidin-4-one derivatives |
| 04/01/2010 | WO2009156861A3 Substituted pyrimidone derivatives |
| 04/01/2010 | WO2009155069A8 Compositions and methods for treating psychiatric and neurodegenerative disorders |
| 04/01/2010 | WO2009154944A3 Pharmaceutical formulations and methods of use which combine non-steroidal anti-inflammatory compounds with anti-hypertensive compounds |
| 04/01/2010 | WO2009154800A3 Compositions and methods for treating lung disorders |
| 04/01/2010 | WO2009154785A3 C4-substituted alpha-keto oxazoles |
| 04/01/2010 | WO2009152374A3 Method for treating chronic wounds with an extracellular polymeric substance solvating system |
| 04/01/2010 | WO2009151762A3 Anticancer methods using extracts of anemarrhena asphodeloides bunge |
| 04/01/2010 | WO2009151620A9 Pain treatment using erk2 inhibitors |
| 04/01/2010 | WO2009151299A3 Styrylbenzofuran derivatives as inhibitors for beta-amyloid fibril formation and preparation method thereof |
| 04/01/2010 | WO2009149435A3 Promoting axon regeneration in the adult cns through control of protein translation |
| 04/01/2010 | WO2009148654A3 Cephalotaxus esters, methods of synthesis, and uses thereof |
| 04/01/2010 | WO2009148605A3 Methods for treating hypercholesterolemia |
| 04/01/2010 | WO2009143064A3 Rice bran extracts for inflammation and methods of use thereof |
| 04/01/2010 | WO2009143019A3 Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity |
| 04/01/2010 | WO2009140675A3 Combination therapy with pm00104 and another antitumor agent |
| 04/01/2010 | WO2009139924A3 Controlled release corticosteroid compositions and methods for the treatment of otic disorders |
| 04/01/2010 | WO2009131669A3 Carbamate and urea inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 04/01/2010 | WO2009125981A9 Pharmaceutical formulation |
| 04/01/2010 | WO2009124734A3 Substituted sulfonamide derivatives |
| 04/01/2010 | WO2009111676A3 Boron-containing small molecules as anti-inflammatory agents |
| 04/01/2010 | WO2009111576A3 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES |
| 04/01/2010 | WO2009111418A3 Ketorolac tromethamine compositions for treating or preventing ocular pain |
| 04/01/2010 | WO2009087675A3 Coated extended release pharmaceutical compositions of levetiracetam |
| 04/01/2010 | WO2009086952A3 Compositions for the treatment of degenerative articular diseases |
| 04/01/2010 | WO2009071993A3 Pharmaceutical compositon for cleansing of the bowel |
| 04/01/2010 | WO2009062576A8 Benzimidazoledihydrothiadiazinone derivatives as fructose-1,6-bisphosphatase inhibitors, and pharmaceutical compositions comprising same |
| 04/01/2010 | WO2009037592A3 Triazole-based aminoglycoside-peptide conjugates and methods of use |
| 04/01/2010 | WO2009027697A3 Non-aqueous pharmaceutical compositions |
| 04/01/2010 | WO2009026135A3 Controlled transdermal bisoprolol delivery system |
| 04/01/2010 | WO2009026133A3 Transdermal bisoprolol delivery system |
| 04/01/2010 | WO2009024541A3 Isoxazoline compositions and their use as antiparasitics |
| 04/01/2010 | WO2008139845A8 Novel amide derivative |
| 04/01/2010 | WO2008121258A8 Methods of treating metabolic syndrome using dopamine receptor agonists |
| 04/01/2010 | WO2008106901A8 A pharmaceutical composition with atorvastatin active ingredient |
| 04/01/2010 | WO2008091618A8 Use of d-ribose to treat cardiac arrhythmias |
| 04/01/2010 | US20100082108 Spine distraction implant and method |
| 04/01/2010 | US20100081810 C-Pyrazole A2A Receptor Agonists |
| 04/01/2010 | US20100081797 Manipulation of Cytokine Levels Using CD83 Gene Products |
| 04/01/2010 | US20100081724 Process of obtainment of trans-resveratrol and/or emodin and nutraceuticcal compositions containing them |
| 04/01/2010 | US20100081723 Memantine For The Treatment Of Childhood Behavioral Disorders |
| 04/01/2010 | US20100081722 Composition and method for neuroprotection against excitotoxic injury |
| 04/01/2010 | US20100081721 Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists |
| 04/01/2010 | US20100081720 Deuterium-enriched atomoxetine |
| 04/01/2010 | US20100081719 Milnacipran for the treatment of fatigue associated with fibromyalgia syndrome |
| 04/01/2010 | US20100081718 Combinations comprising alpha-2-delta ligands |
| 04/01/2010 | US20100081717 Chiral Cyclic Beta-Amino Acids and their Derivatives, Pharmaceutical Compositions Containing Them and the Use of Such Compounds |
| 04/01/2010 | US20100081715 Bioavailability, and prevents recrystallization of fenofibric acid; dosage forms made by melt extrusion |
| 04/01/2010 | US20100081713 Compositions and methods for treating viral infections |
| 04/01/2010 | US20100081712 Recombinant human factor ix and use thereof |
| 04/01/2010 | US20100081711 Cytotoxic agents |
| 04/01/2010 | US20100081710 Modified L-Nucleic Acid |
| 04/01/2010 | US20100081709 Isolated snare ykt6 genomic polynucleotide fragments from chomosome 7 and their uses |
| 04/01/2010 | US20100081708 Anticoagulant compounds |
| 04/01/2010 | US20100081707 Devices and methods for delivering polynucleotides into retinal cells of the macula and fovea |
| 04/01/2010 | US20100081706 Immunomodulatory oliogonucleotides and methods of use therefor |
| 04/01/2010 | US20100081705 Methods for slowing familial als disease progression |
| 04/01/2010 | US20100081704 Modulator compounds of the drug resistance in epithelial tumour cells |